Oxytrol Switch Showcases FDA’s New Benefit-Risk Framework – Soller
This article was originally published in The Tan Sheet
Executive Summary
Self-care expert Bill Soller says FDA approval of the Oxytrol for Women overactive bladder drug as an Rx-to-OTC switch “is a clear expression” of the agency’s qualitative benefit-risk framework for drug reviews, laid out in its recent PDUFA V Implementation Plan.
You may also be interested in...
FDA’s Structured Benefit-Risk Assessment Framework To Come Online In FY 2014
Drug reviews will include a benefit-risk summary assessment that states the rationale for regulatory action on a drug or biologic application and explains how differences of opinion among reviewers were resolved.
Merck’s Oxytrol Could Go From Rx Also-Ran To OTC Star – Analysts
Watson’s Oxytrol currently has just a 1% share of the overactive bladder drug market, but Kline and Kalorama analysts see sizable potential should it switch OTC.
CDER Benefit/Risk Assessment Tool Has Room For OTC Considerations
A new benefit/risk framework for drug reviews currently being tested in FDA requires incremental considerations to apply to OTC reviews, a CDER official says. Former NDAC chairman Brass says FDA’s model is compatible with a separate OTC assessment framework developed for industry.